Source:http://linkedlifedata.com/resource/pubmed/id/20173784
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2010-10-13
|
| pubmed:abstractText |
The effect of natural killer (NK) cell alloreactivity on the outcome of unrelated hematopoietic SCT (HSCT) remains a topic of debate. NK cell alloreactivity after allogeneic HSCT is regulated by killer-cell Ig-like receptors (KIRs). To investigate the influence of KIRs on outcome after unrelated HSCT, we retrospectively analyzed the HLA and KIR genotypes of 116 donor-recipient pairs. We found that missing KIR ligands in recipients were significantly associated with a decreased leukemic relapse risk (P=0.019, HR=0.329), mainly in myeloid disease (P=0.003, HR=0.193). This beneficial effect was seen in AML/myelodysplastic syndrome and also in chronic myeloid leukemia. In myeloid disease, missing KIR ligands also improved 5-year OS (P=0.034, HR=0.430) and disease-free survival (DFS) (P=0.024, HR=0.445). Meanwhile, the presence of donor-activating KIR2DS3 gene was associated with increased relapse risk (P=0.003, HR=5.046), decreased OS (P=0.004, HR=3.181) and DFS (P=0.003, HR=2.919) in myeloid disease. No effect was seen in patients with lymphoid disease. Our study indicated that, in unrelated HSCT for myeloid leukemia, missing KIR ligands in recipients offered a lower relapse risk and a long-term survival advantage. The presence of KIR2DS3 in the donor was an important risk factor for myeloid leukemia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1476-5365
|
| pubmed:author |
pubmed-author:CanAA,
pubmed-author:EmrJJ,
pubmed-author:HuX RXR,
pubmed-author:HuangHH,
pubmed-author:JinA YAY,
pubmed-author:KarP KPK,
pubmed-author:LORR,
pubmed-author:LaiX YXY,
pubmed-author:LinM FMF,
pubmed-author:LuoYY,
pubmed-author:S?laKK,
pubmed-author:ShiJ MJM,
pubmed-author:WuG QGQ,
pubmed-author:XieW ZWZ,
pubmed-author:YuX ZXZ,
pubmed-author:ZhangJJ,
pubmed-author:ZhengW YWY
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
45
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1514-21
|
| pubmed:meshHeading |
pubmed-meshheading:20173784-Adolescent,
pubmed-meshheading:20173784-Adult,
pubmed-meshheading:20173784-Child,
pubmed-meshheading:20173784-China,
pubmed-meshheading:20173784-Female,
pubmed-meshheading:20173784-Genotype,
pubmed-meshheading:20173784-Graft vs Host Disease,
pubmed-meshheading:20173784-HLA Antigens,
pubmed-meshheading:20173784-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20173784-Humans,
pubmed-meshheading:20173784-Leukemia,
pubmed-meshheading:20173784-Leukemia, Myeloid,
pubmed-meshheading:20173784-Ligands,
pubmed-meshheading:20173784-Male,
pubmed-meshheading:20173784-Middle Aged,
pubmed-meshheading:20173784-Neoplasm Recurrence, Local,
pubmed-meshheading:20173784-Receptors, KIR,
pubmed-meshheading:20173784-Retrospective Studies,
pubmed-meshheading:20173784-Risk Factors,
pubmed-meshheading:20173784-Survival Analysis,
pubmed-meshheading:20173784-Tissue Donors,
pubmed-meshheading:20173784-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.
|
| pubmed:affiliation |
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|